Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics.
Saved in:
| Title: | Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics. |
|---|---|
| Authors: | Bibi, David1 (AUTHOR) david.bibi@teva.co.il, Steiner, Lilach1,2 (AUTHOR), Krtalic, Iva2,3 (AUTHOR), Juretic, Marina2,3,4 (AUTHOR), Cetina-Cizmek, Biserka1,2,3 (AUTHOR), Komlosi, Andrea2,4 (AUTHOR), Loupe, Pippa1,3 (AUTHOR), Ferderber, Kristina2,4 (AUTHOR), Hallak, Hussein1 (AUTHOR) |
| Source: | Pharmaceutics. May2026, Vol. 18 Issue 5, p601. 17p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 19994923 |
|---|---|
| DOI: | 10.3390/pharmaceutics18050601 |
